S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU

Oncology Reports

Volumn 16, Issue 3, 2006, Pages 465-471

  Nakata, Eiko ^a   Fukushima, Masakazu ^b   Takai, Yoshihiro ^c   Nemoto, Kenji ^d   Ogawa, Yoshihiro ^a   Nomiya, Takuma ^d   Nakamura, Yasuhiro ^d   Milas, Luka ^e   Yamada, Shogo ^d  

^a TOHOKU UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colon cancer; Radiation; S 1

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; OXONIC ACID; RADIOSENSITIZING AGENT; S 1 (COMBINATION); TEGAFUR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COLORECTAL TUMOR; DRUG COMBINATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OXONIC ACID; RADIATION-SENSITIZING AGENTS; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749169384     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.3.465     Document Type: Article

References (31)

1. Milas L, Mason KA, Liao Z, et al: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 25: 152-167, 2003. (Pubitemid 36133895)
2. Herskovic A, Marts K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New Engl J Med 326: 1593-1598, 1992.
3. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New Engl J Med 338: 1798-1804, 1998. (Pubitemid 28277960)
4. Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Engl J Med 340: 1137-1143, 1999. (Pubitemid 29177872)
5. Furuse K, Fukuoka M and Kawahara M: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999. (Pubitemid 29415225)
6. Rich TA, Shepard RC and Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22: 2214-2232, 2004. (Pubitemid 41095158)
7. Brito RA, Medgyesy D, Zukowski TH, et al: Fluoropyrimidines: a critical evaluation. Oncology 57 (suppl 1): 2-8, 1999. (Pubitemid 29348555)
8. Byfield J: Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Antitumor Drug-Radiation Interactions. Hill BT BA (eds). CRC Press Inc., Boca Raton, FL, pp87-105, 1990.
9. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989. (Pubitemid 19098135)
10. Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
11. Giller SA, Zhuk RA and Lidak M: Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Dokl Akad Nauk SSSR 176: 332-335, 1967.
12. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987. (Pubitemid 17132408)
13. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993. (Pubitemid 23267702)
14. Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. (Pubitemid 26171684)
15. Fukushima M, Shimamoto Y, Kato T, et al: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 9: 817-823, 1998. (Pubitemid 28512890)
16. Sakata Y, Ohtsu A, Horikoshi N, et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
17. Koizumi W, Kurihara M, Nakano S, et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000. (Pubitemid 30189900)
18. Van den Brande J, Schffski P, Schllens JH, et al: EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653, 2003.
19. Taguchi T, Morimoto K, Horikoshi N, et al: An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group). Gan To Kagaku Ryoho 25: 1035-1043, 1998.
20. Inuyama Y, Kida A, Tsukuda M, et al: Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group). Gan To Kagaku Ryoho 25: 1151-1158, 1998.
21. Kawahara M, Furuse K, Sagawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943, 2001. (Pubitemid 33015993)
22. Harada K, Kawaguchi S, Supriatno, et al: Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncology 40: 713-719, 2004. (Pubitemid 38686908)
23. Murakami Y, Kazuno H, Emura T, et al: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 17: 277-283, 2000.
24. Fertil B and Malaise EP: Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Biol 7: 621-629, 1981. (Pubitemid 11072545)
25. Miyamoto S, Boku N, Ohtsu A, et al: Clinical implications of immunoreactivity of thymidilate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Int J Oncol 17: 653-658, 2000.
26. Okabe H, Koizumi K, Tsujimoto H, et al: Rpitope analysis and utility of monoclonal antibodies to native and recombinant human thymidilate synthase. Int J Mol Med 5: 133-138, 2000.
27. Yamachika T, Nakanishi H, Inada K, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therepeutic significance. Cancer 82: 70-77, 1998. (Pubitemid 28070481)
28. Metzger R, Leichman CG, Danenberg KD, et al: ERCC mRNA levels complement thymidylate synthase mRNA levels in predicting responce and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998. (Pubitemid 28041614)
29. Saga Y, Suzuki M, Mizukami H, et al: Enhanced expression of thymidylate synthase mediates resistanceof uterine cervical cancer cells to radiation. Oncology 63: 185-191, 2002.
30. Nakajima Y, Miyamoto T, Tanabe M, et al: Enhancement of mammalian cell killing by 5-Fluorouracil in combination with X-rays. Cancer Res 39: 3763-3767, 1979. (Pubitemid 10220190)
31. Berry RJ: Effects of some metabolic inhibitors on X-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated X-ray doses. Br J Radiol 39: 458-463, 1966.